File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Establishment of platelet donor registry improves the treatment of platelet transfusion refractoriness in Guangzhou region of China

TitleEstablishment of platelet donor registry improves the treatment of platelet transfusion refractoriness in Guangzhou region of China
Authors
Keywordsplatelet transfusion refractory
platelet transfusion
human platelet alloantigen
human leukocyte antigen
Issue Date2010
Citation
Transfusion Medicine, 2010, v. 20, n. 4, p. 269-274 How to Cite?
AbstractPlatelet transfusion refractoriness (PTR) is the major complication of long-term platelet supportive care. To improve the effectiveness of platelet transfusion therapy in PTR patients, we aimed to establish a platelet donor registry in our region (Guangzhou, China) by typing the human leukocyte antigen (HLA) and human platelet antigen (HPA). Blood donors (n = 864) from our population were genotyped for HLA-A, HLA-B and HPA systems by polymerase chain reaction amplification with sequence-specific primer(PCR-SSP) techniques. Using this cohort, we compared the results of platelet transfusions (matched vs. random) in 23 patients with PTR. Matched platelets were selected either by HLA antigen matching or by HLA antibody matching, as predicted by antibody specificity prediction (ASP) analysis. Significantly higher platelet recovery (PPR) values were obtained with HLA-matched platelets in comparison with random platelets. No significant difference in PPR was observed between HLA matching and ASP methods. In two patients, platelet-specific alloantibodies (alloabs) (anti-HPA-3b and anti-HPA-5b) were detected besides HLA class I alloabs. Transfusion with HLA- and HPA-compatible platelets in both the patients resulted in significantly higher PPR when compared with HLA-compatible platelet transfusion alone. In this study, we demonstrated that the establishment of an HLA- and HPA-typed platelet aphaeresis donor registry is useful to improve the treatment outcome of PTR patients and to maintain a long-term platelet transfusion strategy. © 2010 British Blood Transfusion Society.
Persistent Identifierhttp://hdl.handle.net/10722/207040
ISSN
2015 Impact Factor: 1.689
2015 SCImago Journal Rankings: 0.528

 

DC FieldValueLanguage
dc.contributor.authorXia, Wenjie-
dc.contributor.authorYe, Xin-
dc.contributor.authorTian, Linwei-
dc.contributor.authorXu, Xiuzhang-
dc.contributor.authorChen, Yangkai-
dc.contributor.authorLuo, Guangping-
dc.contributor.authorBei, C. H.-
dc.contributor.authorDeng, Jing-
dc.contributor.authorSantoso, Sentot-
dc.contributor.authorFu, Yongshui-
dc.date.accessioned2014-12-09T04:31:17Z-
dc.date.available2014-12-09T04:31:17Z-
dc.date.issued2010-
dc.identifier.citationTransfusion Medicine, 2010, v. 20, n. 4, p. 269-274-
dc.identifier.issn0958-7578-
dc.identifier.urihttp://hdl.handle.net/10722/207040-
dc.description.abstractPlatelet transfusion refractoriness (PTR) is the major complication of long-term platelet supportive care. To improve the effectiveness of platelet transfusion therapy in PTR patients, we aimed to establish a platelet donor registry in our region (Guangzhou, China) by typing the human leukocyte antigen (HLA) and human platelet antigen (HPA). Blood donors (n = 864) from our population were genotyped for HLA-A, HLA-B and HPA systems by polymerase chain reaction amplification with sequence-specific primer(PCR-SSP) techniques. Using this cohort, we compared the results of platelet transfusions (matched vs. random) in 23 patients with PTR. Matched platelets were selected either by HLA antigen matching or by HLA antibody matching, as predicted by antibody specificity prediction (ASP) analysis. Significantly higher platelet recovery (PPR) values were obtained with HLA-matched platelets in comparison with random platelets. No significant difference in PPR was observed between HLA matching and ASP methods. In two patients, platelet-specific alloantibodies (alloabs) (anti-HPA-3b and anti-HPA-5b) were detected besides HLA class I alloabs. Transfusion with HLA- and HPA-compatible platelets in both the patients resulted in significantly higher PPR when compared with HLA-compatible platelet transfusion alone. In this study, we demonstrated that the establishment of an HLA- and HPA-typed platelet aphaeresis donor registry is useful to improve the treatment outcome of PTR patients and to maintain a long-term platelet transfusion strategy. © 2010 British Blood Transfusion Society.-
dc.languageeng-
dc.relation.ispartofTransfusion Medicine-
dc.subjectplatelet transfusion refractory-
dc.subjectplatelet transfusion-
dc.subjecthuman platelet alloantigen-
dc.subjecthuman leukocyte antigen-
dc.titleEstablishment of platelet donor registry improves the treatment of platelet transfusion refractoriness in Guangzhou region of China-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1365-3148.2010.00995.x-
dc.identifier.pmid20136782-
dc.identifier.scopuseid_2-s2.0-77954367337-
dc.identifier.volume20-
dc.identifier.issue4-
dc.identifier.spage269-
dc.identifier.epage274-
dc.identifier.eissn1365-3148-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats